Seeking Alpha

Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today,...

Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%).
Comments (3)
  • sophocles
    , contributor
    Comments (204) | Send Message
     
    I don't understand why ONXX, PCYC and GILD are down
    16 May 2013, 01:41 PM Reply Like
  • edemikat
    , contributor
    Comments (6) | Send Message
     
    All of pharma is down today
    16 May 2013, 04:45 PM Reply Like
  • edemikat
    , contributor
    Comments (6) | Send Message
     
    Alll of pharma is down today
    16 May 2013, 04:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|